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Background: Epicardial adipose tissue (EAT) has been associated with adverse left
atrial (LA) remodeling and atrial fibrillation (AF) outcomes, possibly because of paracrine
signaling.
Objectives: We examined factors associated with a novel measure of EAT i.e., indexed
LAEAT (iLAEAT) and its prognostic significance after catheter ablation (CA) of atrial
fibrillation (AF).
Methods: We performed a retrospective analysis of 274 participants with AF referred for
CA. LAEAT area was measured from a single pre-ablation CT image and indexed to body
surface area (BSA) to calculate iLAEAT. Clinical, echocardiographic data and 1-year AF
recurrence rates after CA were compared across tertiles of iLAEAT. We performed logistic
regression analysis adjusting for factors associated with AF to examine relations between
iLAEAT and AF recurrence.
Results: Mean age of participants was 61 ± 10 years, 136 (49%) were women, mean
BMI was 32 ± 9 kg/m2 and 85 (31%) had persistent AF. Mean iLAEAT was 0.82 ±
0.53 cm2/m2. Over 12-months, 109 (40%) had AF recurrence. Participants in the highest
iLAEAT tertile were older, had higher CHA2DS2VASC scores, more likely to be male, have
greater LA volume, and were more likely to have persistent (vs. paroxysmal) type AF than
participants in the lowest iLAEAT tertile (p for all <0.05). In regression analyses, iLAEAT
was associated with higher odds of AF recurrence (OR = 2.93; 95% CI 1.34–6.43).
Conclusions: iLAEAT can quantify LA adipose tissue burden using standard CT images.
It is strongly associated with AF risk factors and outcomes, supporting the hypothesis
that EAT plays a role in the pathophysiology of AF.
Keywords: atrial fibrillation, epicardial adipose tissue, cardiac CT, catheter ablation, recurrence, left atrial
remodeling
Sanghai et al. Epicardial Fat Predicts AF Outcomes
INTRODUCTION
Population-based studies have demonstrated that visceral
adipose tissue is strongly associated with cardiovascular disease
including coronary atherosclerosis, carotid stenosis, heart
failure and atrial fibrillation (AF) (1–6). This is partly due
to the close relationship between visceral adiposity and
increased burden of adverse metabolic factors, such as diabetes
mellitus and hypertension (7, 8). Imaging techniques such as
echocardiography, cardiac computed tomography (CCT) and
magnetic resonance imaging provide a more precise assessment
of visceral adiposity (9–11) than anthropometric measures
such as body mass index (BMI) and waist circumference (12).
Epicardial adipose (EAT) tissue is the visceral adipose depot of
the heart. It is directly adjacent to the myocardium, contained
within the visceral pericardium (13). Periatrial adipose tissue is
tightly linked to markers of atrial remodeling and vulnerability
to AF, perhaps due to paracrine and/or vasocrine effects (14–
18) and/or interactions with the cardiac inputs of the autonomic
nervous system (19, 20). Recent studies have shown that atrial
adipose tissue relates to recurrence of AF after catheter ablation
(11, 21–24). However, it remains unknown whether it confers
risk independent of total body mass or visceral adiposity.
To overcome these limitations, we propose to calculate an
indexed left atrial EAT (iLAEAT) derived by adjusting LA
EAT measured on quantitative CCT based on body surface
area (BSA). Using data from a prospective treatment registry
including AF patients undergoing catheter ablation, CCT and
echocardiographic cardiac phenotyping, we sought to examine
associations between an iLAEAT, parameters of adverse cardiac
remodeling, as well as type of AF and recurrence of AF after
ablation.
METHODS
Patient Population
We reviewed the medical records of 420 consecutive participants
with AF who were referred to the University of Massachusetts
Medical Center (UMMC) Atrial Fibrillation Clinic for AF
ablation between November 2011 to April 2016. All participants
underwent a pre-ablation CCT scan and an echocardiogram
within 3 months of the procedure. Late AF recurrence was
adjudicated for 312 patients. Twenty-nine were excluded due
to significant mitral valve pathology on echocardiography to
restrict the sample to subjects with true “non-valvular” AF.
Nine subjects were excluded since their CCT scans were not
available for review. Thus, 274 were included in the final analysis.
Participants were prospectively studied to determine recurrence
of AF after ablation. The study was approved by the University
of Massachusetts Medical School Institutional Review Board
(IRB#00003865).
Clinical Variables
Demographic information, including age, gender and race were
abstracted from the health record by trained study staff. Clinical
covariates abstracted included diabetes mellitus, hypertension,
dyslipidemia, heart failure, coronary artery disease, obstructive
sleep apnea, stroke and peripheral vascular disease. Trained staff
calculated the CHA2DS2VASC score for each patient using the
following variables- congestive heart failure (or Left ventricular
systolic dysfunction), hypertension, age 65–74 years (1 point)
age ≥ 75 years (2 points), diabetes mellitus, prior stroke or
TIA or thromboembolism (2 points), vascular disease (e.g.,
peripheral artery disease, myocardial infarction, aortic plaque)
and gender (i.e., female sex) (25). The burden of pre-existing
AF was classified at the time of the index ablation by trained
electrophysiology fellows or advanced care practitioners who
assisted with the procedure [3 categories: paroxysmal (at least
1 day of AF but <7 consecutive days of AF), persistent
(at least 7 consecutive days with >23 h of AF) or long-
standing persistent (>6 months of AF)]. BSA was calculated
for each patient using their documented height and weight
at the time of the CCT imaging using the Mosteller formula
(26).
Catheter Ablation for Atrial Fibrillation
All patients enrolled in the UMMC AF registry underwent
catheter ablation using radiofrequency ablation or cryoablation
by one out of five board certified electrophysiologists. A
standardized approach was used in almost all cases. In patients
who had a radiofrequency ablation procedure, a wide area
circumferential ablation was performed with an open irrigated
or 8mm radiofrequency ablation catheter. For cryoablation
procedures, pulmonary vein isolation was performed using the
Arctic Front cryoballoon catheter (28 or 23mm, Medtronic
Inc. Minneapolis, MN). Cryoablation was done twice in each
pulmonary vein for 150–240 s. Both entry and exit block was
confirmed using a circular mapping catheter. Patients with
persistent AF received additional lesions at the left atrial
roof, the basal posterior wall, and the left atrial isthmus
at the discretion of the operating electrophysiologist. Anti-
arrhythmic medications were stopped at the discretion of
the treating electrophysiologist if there was no symptomatic
or electrocardiographic evidence of AF recurrence. Oral
anticoagulation with warfarin or direct oral anticoagulant
was continued for at least 1 month as determined by the
treating physician, typically based on the participant’s baseline
CHA2DS2VASC risk score.
Echocardiographic Measurements
Left ventricular (LV) and LA volumes were measured according
to the American Society of Echocardiography guidelines for
chamber quantification (27). Pulsed wave tissue Doppler imaging
was used to acquire mitral inflow velocity (E) and mitral annular
velocities (e’) to estimate LV filling pressures (E/e’) (28). Right
ventricular (RV) systolic function was assessed by calculating
fractional area change in the RV- focused apical 4-chamber view.
All measurements were averaged over 3 beats when AF was
present (29). Cardiac chamber dimensions as well as LV ejection
fraction were acquired directly from the echocardiogram reports.
Doppler velocities and RV fractional area change were measured
by one of the authors (SRS). The intra-observer reproducibility
was r = 0.94.
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FIGURE 1 | Example of a study participant showing EAT measurement in a
single CT image using a 4-chamber equivalent view. Areas in red depict traced
EAT with their respective areas and Hounsfield Units.
EAT Quantification
CCT imaging was performed using a Siemens Somatom
Definition Flash 128 slice dual source CT Scanner. Unenhanced
scans were acquired with a high-pitch FLASH protocol. Contrast
enhanced scans were acquired using a sequential acquisition
protocol with injection of low ionic contrast. Contrast timing
was calculated using a 15ml contrast test bolus followed by 50ml
saline at 5–6 ml/s. EAT area was measured by CCT in a single
cross section using a 4-chamber equivalent view placing the true
LV apex in view. Areas of EAT surrounding the LA, RA, LV,
and RV were separately assessed by tracing regions of interest
(ROI) containing heart and EAT (Figure 1). ROI’s were placed
at the visceral epicardium to exclude pericardial fluid. This was
done by two authors (SRS and BH). Separate values for EAT
surrounding the four chambers were recorded and added to
obtain total EAT. The upper threshold limit of CCT attenuation
for the identification of EAT was defined at (-) 43 Hounsfield
units (HU) for unenhanced scans and at (-) 15 HU for contrast
enhanced scans as described previously (10).
Outcomes Adjudication
All participants were followed for at least 12 months following
their ablation procedure according to a standard protocol.
Recurrence of AF was determined from all available clinic and
hospital notes, 12 lead electrocardiograms, and cardiac monitor
data. Twelve-lead electrocardiograms were ordered at 1, 3, 6,
and 12 months and a 7-day cardiac event monitor was typically
prescribed at 3-months after the procedure. Additional ECGs
and monitor recordings were obtained if the participant had any
symptoms suspicious of AF (such as chest pain, palpitations,
shortness of breath). Recurrence of AF was defined as any
evidence of AF on a 12 lead ECG or greater than 20 s of AF on
a cardiac monitor and was confirmed by an electrophysiologist.
Any electrical or pharmacologic cardioversion or repeat ablation
within the follow up period was characterized as AF recurrence.
Any recurrence of AF after the initial blanking period of 3
months, were considered as significant (30).
Statistical Analysis
Participants were divided into tertiles based on their iLAEAT
measures reported as low, intermediate and high. This was
done to identify participants at the highest risk for AF
recurrence post ablation thus providing a clinically relevant
risk predictor. We examined the relationship between iLAEAT
tertiles and demographics, medical history, echocardiographic
and biochemical factors. We used analysis of variance and
chi-squared statistic to test for difference in continuous and
categorical factors respectively among the tertiles. Multivariable
logistic regression analysis was used to examine the relationship
of clinical, electrocardiographic and echocardiographic
predictors with type of AF and AF recurrence. Co-variates
used in the multivariable models were selected a priori based
on previously known associations with AF severity, AF type
and AF recurrence (BMI, CHA2DS2VASC, E/e’, LA volume,
LV mass index). CHA2DS2VASC score was used in place of
individual component variables to avoid overfitting of the
regression model. Subsequently, we conducted several stratified
analyses to examine iLAEAT relations with AF recurrence after
CA among participants of different ages, genders, types of AF
and based on their BMI. We considered p < 0.05 as significant.
Statistical analyses were performed using MedCalc (v16.2.1.0-64
bit, MedCalc software, Mariakerke, Belgium) and SAS (9.4)
software.
RESULTS
The baseline characteristics of all registry participants who
had AF ablation during the study period and current study
participants are shown in Table 1. The mean age of the study
cohort was 61 ± 10 years, 136 (49%) were female, mean
BMI was 32 ± 9 kg/m2 and cohort participants had a mean
CHA2DS2VASC of 2.2 ± 1.5, suggesting that majority of the
participants had moderate or greater burden of cardiovascular
comorbidities. Eighty-five participants (31%) had persistent
AF and 239 (87%) were on anti-arrhythmic drugs before
ablation. The mean LV ejection fraction among participants
was 58 ± 7% and the mean LA volume was 87 ± 29ml.
Most participants 195 (72%) underwent cryoablation and the
remainder underwent radiofrequency ablation. Over a 12-month
period of standardized, intensive follow up, 109 (40%) of
participants had at least one recurrence of AF. Of these, 48
individuals (44%, n = 109) underwent a repeat ablation and 28
underwent (26%, n= 109) a cardioversion.
The inter and intra-observer reproducibility for EAT
measurement was (r = 0.89 and 0.95), respectively. For 10
randomly selected study participants, we measured the time
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required for measuring EAT surrounding the LA, LV, and RV
separately. The median time required for reporting EAT for
TABLE 1 | Baseline characteristics of All Registry Participants and Study
participants.
Variables All registry participants
(n = 420)
Study participants
(n = 274)
Age, years 61 ± 10 61 ± 10
Female sex 184 (44) 136 (49)
Systolic BP, mmHg 128± 18 127 ± 16
BMI, kg/m2 32 ± 16 32 ± 9
Current smoker 54 (13) 38 (14)
Persistent AF 123 (29) 85 (31)
CHA2DS2VASC score 2.1 ± 1.4 2.2 ± 1.5
Prior antiarrhythmic drugs 373 (89) 239 (87)
Hypertension 300 (71) 195 (71)
Diabetes 81 (19) 56 (20)
Heart Failure 68 (16) 33 (12)
CAD 85 (20) 62 (22)
Obstructive sleep apnea 156 (37) 108 (39)
Stroke/TIA 20 (5) 18 (6)
PAD 47 (11) 30 (11)
Cryo ablation 295 (70) 195 (72)
Late AF recurrence
†
123 (39) 109 (40)
Continuous variables are presented as mean ± standard deviation and categorical
variables are presented as n (%). AF, Atrial Fibrillation; BMI, Body Mass Index; BP, Blood
Pressure; CAD, Coronary Artery Disease; PAD, Peripheral Arterial Disease; TIA, Transient
Ischemic Attack.
†
No. of patient in whom AF recurrence outcome was adjudicated was
312.
an experienced operator (>100 prior measurements) was 71 s
(range 55–92 s).
Mean iLAEAT among participants was 0.82 ± 0.53 cm2/m2.
Participants in the high tertile of iLAEAT when compared to
participants in the low iLAEAT tertile tended to be older (63± 9
vs. 60± 10, p= 0.04), have a higher mean CHA2DS2VASC score
(2.6 ± 1.5 vs. 2.0 ± 1.4, p < 0.01), were less likely to be female
(46% vs. 61%, p = 0.04), and more likely to have persistent AF
(43.9% vs. 14.3%, p < 0.01) (Table 2A).
iLAEAT Relates to Echocardiographic and
Electrocardiographic Measures of Cardiac
Structure and Function
Participants in the highest tertile of iLAEAT had a greater LA
volume (90 ± 28ml vs. 81 ± 29ml, p = 0.04). The groups did
not differ significantly with respect to LVEF, LV mass, diastolic
function or RV function (Table 2). Similarly, sinus node recovery
time and QRS duration did not differ among the three groups.
The PR interval was longer in participants with highest iLAEAT
(184 ± 30ms in the highest tertile vs. 167 ± 40ms in the lowest
iLAEAT tertile, p= 0.02).
iLAEAT Relates to Validated Biomarkers of
AF Recurrence
A significantly greater proportion of participants in the highest
iLAEAT tertile had persistent AF as compared to the lowest tertile
(43.9% persistent AF in the highest iLAEAT tertile vs. 14.3% in
the lowest tertile, p < 0.01). Higher iLAEAT was also associated
with higher circulating C-reaction protein (CRP) levels (4.1± 1.7
mg/L vs. 2.8± 2.6 mg/L, p= 0.01) (Table 2B).
Table 2A | Baseline clinical characteristics of study participants stratified by iLAEAT.
Variables Lowest iLAEAT tertile (n = 92)
(0–0.51)
Intermediate iLAEAT tertile
(n = 91) (0.52–0.94)
Highest iLAEAT tertile
(n = 91) (0.95–2.83)
P-value
Mean iLAEAT 0.31 ± 0.14 0.72 ± 0.13 1.42 ± 0.42 –
Age, years 60 ± 10 60 ± 11 63 ± 9 0.04
Female sex 56 (61) 40 (44) 42 (46) 0.04
Systolic BP, mmHg 127 ± 20 127 ± 16 132 ± 19 0.09
BMI, kg/m2 32 ± 12 32 ± 6 32 ± 6 0.96
Current smoker 35 (38) 32 (35) 40 (70) 0.3
Persistent AF 13 (14) 32 (35) 40 (44) <0.01
CHA2DS2VASC score 2 ± 1.4 2 ± 1.5 2.6 ± 1.5 <0.01
Prior antiarrhythmic drugs 80 (87) 80 (88) 79 (87) 0.97
Hypertension 56 (36) 64 (70) 75 (82) <0.01
Diabetes 18 (20) 12 (13) 26 (29) 0.03
Heart Failure 6 (7) 10 (11) 17 (19) 0.04
CAD 18 (20) 15 (17) 29 (32) 0.03
Obstructive sleep apnea 34 (37) 37 (41) 37 (41) 0.84
Stroke/TIA 6 (7) 5 (5) 7 (8) 0.84
PAD 12 (13) 10 (11) 8 (9) 0.64
Late AF recurrence 24 (26) 36 (40) 49 (54) <0.01
Continuous variables are presented as mean ± standard deviation and categorical variables are presented as n (%). AF, Atrial Fibrillation; BMI, Body Mass Index; BP, Blood Pressure;
CV, Cardioversion; CAD, Coronary Artery Disease; PAD, Peripheral Arterial Disease; TIA, Transient Ischemic Attack.
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Table 2B | Baseline echocardiographic, electrocardiographic and biochemical differences of study participants stratified by iLAEAT.
Variables Lowest iLAEAT tertile (n = 92) Intermediate iLAEAT tertile (n = 91) Highest iLAEAT tertile (n = 91) P-value
LVEF, % 59 ± 8 58 ± 9 58 ± 7 0.68
LVMI, gm/m2 83 ± 22 83 ± 25 82 ± 22 0.99
LAV, ml 81 ± 29 91 ± 28 90 ± 28 0.04
E/e’ 9 ± 3 9 ± 4 10 ± 4 0.41
E/A 1.4 ± 0.6 1.8 ± 2.6 1.4 ± 1 0.35
RV FAC, % 41 ± 9 41 ± 9 42 ± 7 0.84
SNRT, ms
†
1048 ± 436 1115 ± 806 1203 ± 641 0.59
PR duration, ms 167 ± 40 174 ± 37 184 ± 30 0.02
QRS duration, ms 103 ± 22 107 ± 65 105 ± 50 0.91
CRP mg/L
†
2.8 ± 2.6 6 ± 2.8 4.1 ± 1.7 0.01
†
Number of participants for which these data were available: SNRT = 53; CRP = 85. CRP, C-reactive Protein; E/A, Mitral inflow E velocity/Mitral inflow A velocity ratio; E/e’ avg, Mitral
inflow E velocity/average tissue Doppler e’ velocity ratio; LAV, Left Atrial volume; LVEF, Left Ventricular Ejection Fraction; LVMI, Left Ventricular Mass Index; RV FAC, Right Ventricular
Fractional Area Change; SNRT, Sinus Node Refractory Time.
iLAEAT Relates to Pre-Ablation AF Type
and Clinically Significant AF Recurrence
After Catheter Ablation
Participants in the highest iLAEAT tertile were significantly
more likely to experience late AF recurrence post ablation than
participants in the lowest tertile [49(53.8%) vs. 11 (12%), p
< 0.01]. In multivariable adjusted analyses (Tables 3A,B), high
iLAEAT was associated with both AF type (OR 4.5, 95% CI 1.76–
11.49), and AF recurrence (OR 2.93, 95% CI 1.34–6.43). There
was a trend toward greater AF recurrence among participants in
the intermediate tertile of iLAEAT but did not reach statistical
significance (OR 1.66, 95% CI 0.76–3.59). In stratified analyses
(Figure 2), iLAEAT was associated with AF recurrence among
individuals with paroxysmal AF (OR 3.43, 95% CI 1.77–6.77) as
opposed to persistent AF (OR 1.47, 95% CI 0.66–3.3). However,
the absolute number of patients with persistent AF in our sample
was relatively low (n = 85). In addition, the association between
iLAEAT and AF recurrence was statistically significant among
participants with BMI >30 kg/m2, whereas iLAEAT was not
significantly associated with AF recurrence among individuals
with a BMI less than 30 kg/m2 (OR 3.93, 95% CI 1.99–7.75 vs.
OR 2, 95% CI 0.93–4.35).
DISCUSSION
In our moderately sized cohort of prospectively enrolled subjects
undergoing index ablation for symptomatic AF, we observed that
a novel CCT-based measure of epicardial adipose tissue, iLAEAT,
was significantly associated with echocardiographic measures
of pathological LA remodeling, burden of pre-existing AF, and
greater likelihood of clinically significant AF recurrence over a 1-
year follow-up period. Our study further supports the hypothesis
that epicardial adipose tissue plays an important role in the
pathophysiology and natural history of AF and may serve as a
phenotype of great use in predicting arrhythmia-free survival
after catheter ablation.
Epicardial fat is a potential contributor to atrial inflammation
and pathological remodeling.
EAT is a metabolically active organ that generates various
bioactive substances (e.g., leptin, nitric oxide) involved
in endothelial vasodilation, inhibition of vascular smooth
muscle proliferation, and inhibition of acetylcholine-mediated
vasoconstriction (13). Excess EAT promotes inflammation
via paracrine effects (i.e., through tumor necrosis factor-
alpha, interleukin-6, and other cytokines) (8). Using data
from the Framingham Heart Study, we found that circulating
adipocytokines relate to pathological cardiac remodeling on
echocardiography (14). Specifically, higher circulating levels
of adiponectin and resistin, cytokines secreted by visceral fat,
are associated with lower LV mass, larger LA size, and lower
LV fractional shortening. The fact that CRP levels were greater
in participants in the highest tertile of iLAEAT, suggests that
epicardial fat is associated with local and, possibly, systemic
inflammation. Although epicardial fat may have direct local
inflammatory effects, we hypothesize that patients in the highest
tertile of iLAEAT had greater visceral adiposity, which is turn
is more likely to be responsible for systemic inflammation (i.e.,
elevated CRP) in this group. Epicardial fat thickness correlates
very closely with visceral adiposity and has been proposed as a
simple non-invasive imaging biomarker of cardiometabolic risk
for this reason (8).
Fat Adjacent to the LA Also Influences LA
Electromechanical Function
In a group of 1946 Framingham Heart Study participants, total
pericardial fat on CCT was associated with atrial conduction
defined by P wave indices (31). Other studies showed good
correlation between total pericardial fat volume and regions
of complex fractionated atrial electrograms (32) as well as
epicardial fat volume correlated well with high dominant
frequency regions (33) thus contributing to the maintenance of
AF. The strong relations between iLAEAT and pathological atrial
electrophysiological remodeling explain why participants in the
highest tertile of iLAEAT in our study had longer PR intervals
than those in the lowest tertile.
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Table 3A | Association of iLAEAT with persistent AF (vs. paroxysmal AF) in multivariable regression models.
Predictor variable Unadjusted OR (95% CI) P-value Model 1 OR (95% CI) P-value Model 2 OR (95% CI) P-value
Highest iLAEAT tertile 4.77 (2.33–9.77) <0.01 4.71 (2.28–9.74) <0.01 4.5 (1.76–11.49) <0.01
Intermediate iLAEAT tertile 3.29 (1.59–6.82) <0.01 3.3 (1.59–6.83) <0.01 2.63 (1.03–6.68) 0.04
Lowest iLAEAT tertile 1 – 1 – 1 –
Model 1, Multivariate model adjusting for CHA2DS2Vasc score and Body Mass Index.
Model 2, Model 1+ LA Volume, LV mass index, average E/e’.
Table 3B | Association of iLAEAT with late AF recurrence in multivariable regression models.
Predictor variable Unadjusted OR (95% CI) P-value Model 1 OR (95% CI) P-value Model 2 OR (95% CI) P-value
Highest iLAEAT tertile 3.31 (1.78–6.16) <0.01 3.2 (1.71–6) <0.01 2.93 (1.34–6.43) 0.01
Intermediate iLAEAT tertile 1.86 (0.99–3.47) 0.05 1.86 (0.99–3.49) 0.05 1.66 (0.76–3.59) 0.2
Lowest iLAEAT tertile 1 – 1 – 1 –
Model 1, Multivariate model adjusting for CHA2DS2Vasc score and Body Mass Index.
Model 2, Model 1+ LA Volume, LV mass index, average E/e’.
FIGURE 2 | Forest plot showing relation between iLAEAT and AF recurrence
stratified according to Age, Gender, BMI and AF type.
iLAEAT, AF Burden and Recurrence
Prior studies have shown that epicardial fat relates to recurrence
of AF after catheter ablation (11, 21–24). However, it remains
unknown whether it confers risk independent of total visceral
adiposity since prior studies did not adjust for body mass.
In one such study, 110 participants underwent periatrial
and periventricular fat measurement on cardiac MRI using
proprietary software. They showed that both measures were
strongly associated with severity of AF and short-term recurrence
after ablation (11). Apart from the difference in imaging, these
investigators used a 3-month cut off for outcomes adjudication as
compared to the 1-year follow-up period employed in our study.
In another study of 600 participants undergoing radiofrequency
ablation and an automated assessment of epicardial fat volume
on CCT (21), total pericardial fat was independently associated
with AF recurrence in patients with persistent AF but not in
paroxysmal AF. Reasons for differences in our findings may
include the fact that prior investigators did not measure atrial
iLAEAT, instead focusing on overall epicardial fat burden. This
is significant because prior studies have shown that periatrial fat
is more tightly linked to the incidence and recurrence of AF than
periventricular fat (22, 23).
In our study, we indexed LA adipose tissue to BSA to
reduce the known relations of gender and total body size
on LA structure and visceral adiposity (34). This is akin
to the approach proposed for LA volumetric assessment in
the American Society of Echocardiography guidelines for
chamber quantification (27). Our stratified analysis shows
that iLAEAT predicts AF recurrence among individuals
with a BMI greater than 30 kg/m2. This may relate to
the association between visceral adiposity, metabolic
dysregulation, and AF recurrence (35, 36). Our findings
show that iLAEAT is an independent predictor of AF burden
and recurrence that may be clinically useful. Our hypothesis
is supported by other investigations showing that indexed
epicardial fat volume is tightly associated with major adverse
cardiovascular events as well as coronary plaque volume
(37, 38).
Strengths and Limitations
Our study demonstrates that iLAEAT is a novel parameter that
can be easily obtained from routinely obtained pre-ablation CT
scans. This was performed in under 2min by an experienced
operator as opposed to a processing time of 5 to 11min
reported for volumetric measurements (10). Its serves as a
readily available discriminatory tool for AF recurrence which
requires minimal operator training and no additional cost.
Thus, iLAEAT may be a powerful additional tool in guiding
therapeutic decision making regarding CA in AF patients. This
study leverages robust data from a comprehensive AF registry
containing accurate, up to date and systematically collected
clinical, echocardiographic and rigorously adjudicated outcomes.
In addition, we systematically measured echocardiographic and
CCT phenotypes using a standardized technique blinded to AF
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status or outcomes. However, this study has a few limitations.
This is a retrospective analysis of prospectively gathered data
which limits the assessment of causality. We were unable to
perform age, gender and BMI matched case-control analyses.
Also, we did not measure anthropologic metrics and biochemical
markers such as interleukins, tumor necrosis factor-alpha, and
hemoglobin A1C which may have added to our understanding
of the mechanisms underlying the proposed association. We
recognize that this is a moderately sized cohort and may
be under-powered to detect certain differences. Validation of
these findings in a larger cohort is warranted. Volumetric
assessment of epicardial fat was not available. However, the cost,
need for specialized software and significant time associated
with obtaining the measurements using cumbersome software
makes it impractical to obtain fat volumes in every patient.
On the contrary, many centers routinely obtain Cardiac CT
scans for defining pulmonary vein anatomy. Hence, we believe
that routine use of iLAEAT to guide prognosis is more
feasible.
CONCLUSIONS
In this study, we demonstrated that iLEAT is associated with
adverse cardiac structure, function, as well as AF type and
AF recurrence after catheter ablation. Since CCT is routinely
obtained in patients prior to AF ablation, measurement of
iLAEAT may help risk stratification for AF prognosis beyond
traditional clinical risk factors. Furthermore, our findings suggest
a strong pathophysiological connection between epicardial fat
and atrial remodeling. Research is needed to examine the
underlying biochemical, electrical and structural mechanisms
underlie the strong associations observed in our study between
visceral, epicardial adipose tissue and AF.
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